BEBT-607 — Investigational Agent
KRAS Inhibitor · Phase 1 · BeBetter Med
Mechanism of Action
An orally bioavailable small-molecule inhibitor that covalently locks KRAS G12C in its inactive GDP-bound state, blocking downstream MAPK signaling in KRAS G12C-mutant tumors.
Investigational Indications
- KRAS G12C-mutant non-small cell lung cancer
- KRAS G12C-mutant colorectal cancer
- Other KRAS G12C-mutant solid tumors